Cardiff scientists uncover mechanism that leads to rare blood clots after AstraZeneca vaccine, UK Covid Vaccine Research Hub
A team of scientists from Cardiff University and the US have identified the biological mechanism that causes extremely rare blood clots following a dose of the AstraZeneca vaccine.
The research, published in the journal Science Advances, used a technique called cryo-electron microscopy to capture images of the adenovirus in molecular detail, in a bid to understand what was causing the clots.
Concerns about the rare blood clots have influenced policy decisions about how the vaccine should be used, and led to restrictions on its use in the UK for people under 40. The Cardiff team were given emergency government funding to ...
Source: Current Awareness Service for Health (CASH) - December 2, 2021 Category: Consumer Health News Source Type: news
Covid: scientists find possible trigger for AstraZeneca jab blood clots
Experts hope better understanding of rare side effect of vaccine could help ‘turn the tide’ on pandemicCoronavirus – latest updatesSee all our coronavirus coverageScientists believe they may have found the trigger behind theextremely rare blood clot complications stemming from the Oxford/AstraZeneca ’s Covid vaccine.According to a team of researchers from Cardiff and the US, the reaction can be traced to the way the adenovirus used by the vaccine to shuttle the coronavirus ’s genetic material into cells binds with a specific protein in the blood, known as platelet factor 4 (PF4).Continue reading... (Source: Guard...
Source: Guardian Unlimited Science - December 2, 2021 Category: Science Authors: PA Media Tags: Coronavirus AstraZeneca Vaccines and immunisation Health Infectious diseases Science Microbiology Medical research Society World news Pharmaceuticals industry Business Source Type: news
A New Study Makes the Case for Mixing and Matching the Pfizer-BioNTech, Moderna and J & J Vaccine Doses
As soon as health officials made it clear that the world would need a booster dose of the COVID-19 vaccine, they needed to know if people could mix doses of vaccines made by different manufacturers.
In the first study to provide results on such cross-dosing, researchers say that it’s safe for people who received one of the three vaccines available in the U.S. to get a booster dose of another—and that they found early evidence that certain combinations might generate stronger immune responses than others. The study was published on a preprint server and not yet peer-reviewed, and came on the same day that the Fo...
Source: TIME: Health - October 15, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
What Causes Facial Pain?
Discussion
Dental caries are one of the most common infections. It is usually caused by Streptococcus viridans. Dental caries are also quite preventable with brushing the teeth at least twice a day with a fluoridated dentifrice, use of dental floss, and preventative dental appointments with application of fluoride varnish and sealants as appropriate. Fluoridated water supplies also help. A review can be found here.
Facial pain is often acute, self-limited and etiologies that may be obvious such as trauma or infection. Facial pain can also overlap with cranial pain (mainly headache), neck pain (often lymphadenopathy or musc...
Source: PediatricEducation.org - October 4, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
NEW BRUNSWICK, N.J., September 13, 2021 – Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), generated robust humoral (antibody) immune responses in adults and children (ages 1-17) with the immune responses persisting in adults for at least two years. The data also showed that booster vaccination with Ad26.ZEBOV, administered to adults two years after the initial vaccination, induced a strong anamnestic (immune) response within seven days. These findings support the potential p...
Source: Johnson and Johnson - September 13, 2021 Category: Pharmaceuticals Source Type: news
Via Nova Therapeutics Announces $20 Million Series A Financing from Aditum Bio to Advance Four Antiviral Programs
OAKLAND, Calif., Sept. 7, 2021 -- (Healthcare Sales & Marketing Network) -- Via Nova Therapeutics announced today that it has closed its Series A financing and raised $20 million from Aditum Bio to advance the development of four preclinical antiviral pro... Biopharmaceuticals, Venture Capital Via Nova Therapeutics, influenza, adenovirus, rhinovirus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
This study is being conducted in the Americas and Europe where different strains of HIV are circulating. Given these differentiating factors and following consultations with the Mosaico study independent Data and Safety Monitoring Board (DSMB), it was decided that the Mosaico study will continue at this time. “We are extremely grateful to the women who volunteered for the Imbokodo study, and to our partners, including the people on the frontlines, all of whom are contributing every day to this enduring quest to make HIV history,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Of...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Mayo Clinic Q & amp;A podcast: How Mayo hopes to slam the door when COVID-19 comes knocking
The COVID-19 pandemic has brought public awareness to vaccines and how vaccines work. A vaccine is any agent that causes the immune system to remember a specific disease-causing entity, thereby preventing future infections. In the case of COVID-19, that's a coronavirus. At Mayo Clinic, decades of research have led to development of a new vaccine platform — a single-cycle adenovirus nasal vaccine — that is now being tested in a phase 1 clinical trial for COVID-19.… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 9, 2021 Category: Databases & Libraries Source Type: news
Take your best shot: Which SARS-CoV-2 vaccine should I get, if any?
(University of Cincinnati) Researchers at the University of Cincinnati College of Medicine have developed a computerized decision analytic model to compare projected outcomes of three vaccine strategies: a patient opts for a messenger RNA vaccine, a patient decides to get an adenovirus vector vaccine or the patient simply forgoes a vaccine altogether. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 20, 2021 Category: Infectious Diseases Source Type: news
The virus trap
(Technical University of Munich (TUM)) To date, there are no effective antidotes against most virus infections. An interdisciplinary research team at the Technical University of Munich (TUM) has now developed a new approach: they engulf and neutralize viruses with nano-capsules tailored from genetic material using the DNA origami method. The strategy has already been tested against hepatitis and adeno-associated viruses in cell cultures. It may also prove successful against corona viruses. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2021 Category: International Medicine & Public Health Source Type: news
I Got a J & J Vaccine. Should I Get a Booster Shot as Delta Spreads?
Welcome to COVID Questions, TIME’s advice column. We’re trying to make living through the pandemic a little easier, with expert-backed answers to your toughest coronavirus-related dilemmas. While we can’t and don’t offer medical advice—those questions should go to your doctor—we hope this column will help you sort through this stressful and confusing time. Got a question? Write to us at covidquestions@time.com.
Today, N.C. in Washington, D.C., asks:
I got a Johnson & Johnson vaccine. With the Delta variant spreading, I’ve heard that some people in my position are also getting s...
Source: TIME: Health - July 8, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID Questions COVID-19 Source Type: news
I Got a J & J Vaccine. Should I Get a Booster Shot as Delta Spreads?
Welcome to COVID Questions, TIME’s advice column. We’re trying to make living through the pandemic a little easier, with expert-backed answers to your toughest coronavirus-related dilemmas. While we can’t and don’t offer medical advice—those questions should go to your doctor—we hope this column will help you sort through this stressful and confusing time. Got a question? Write to us at covidquestions@time.com.
Today, N.C. in Washington, D.C., asks:
I got a Johnson & Johnson vaccine. With the Delta variant spreading, I’ve heard that some people in my position are also getting s...
Source: TIME: Science - July 8, 2021 Category: Science Authors: Jamie Ducharme Tags: Uncategorized COVID Questions COVID-19 Source Type: news
New vaccine platform invented by Mayo enters COVID-19 clinical trial
A Mayo Clinic lab member is purifying an adenovirus vector for preclinical testing. A novel single-cycle adenovirus vaccine platform developed by Mayo Clinic will be used to target multiple infectious diseases and cancer indications, beginning with a phase 1 clinical study using the platform as a vaccine for COVID-19. Developed to enhance the expression of target antigens, the single-cycle adenovirus platform is under investigation for its ability to amplify immune responses. In contrast to replication-defective… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 6, 2021 Category: Databases & Libraries Source Type: news
Improving Cancer Immunotherapy with Anti-Cancer Adenoviruses
Researchers use a mesenchymal stromal cell-based vector to deliver multiple viruses simultaneously to improve CAR-T cell anti-tumor activity. (Source: The Scientist)
Source: The Scientist - June 25, 2021 Category: Science Tags: The Marketplace Source Type: news
Microscopy deep learning predicts viral infections
(University of Zurich) When viruses infect cells, changes in the cell nucleus occur, and these can be observed through fluorescence microscopy. Using fluorescence images from live cells, researchers at the University of Zurich have trained an artificial neural network to reliably recognize cells that are infected by adenoviruses or herpes viruses. The procedure also identifies severe acute infections at an early stage. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 21, 2021 Category: Infectious Diseases Source Type: news
